44results about How to "Lower viral load" patented technology

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

The invention discloses compounds having virus resistance and a composition thereof. The composition comprises one or more of the 13 compounds comprising 6'-O-caffeoyl deacetyl asperulosidic acid methyl ester. The compounds having virus resistance and the composition thereof can be extracted from plants and can also be prepared by synthesis. The composition comprising the compounds having virus resistance can prevent and treat viral infection-caused diseases such as influenza, myocarditis, conjunctivitis, viral pneumonia, encephalitis, leukemia, hepatitis B, hepatitis C, AIDS, genitourinary system infection, EB virus infection, human papillomavirus infection and cytomegalovirus infection. The composition can be prepared into an oral preparation, an injection, a spray, a subcutaneous injection and an anus suppository.

The invention discloses a recombinant novel coronavirus (SARS-CoV-2) vaccine composition. The vaccine composition comprises a recombinant spike protein with an amino acid sequence shown in SEQ ID NO:1. The vaccine composition further comprises a pharmaceutically acceptable carrier, such as an aluminum adjuvant in combination with a CpG ODN adjuvant. The vaccine composition shows excellent immunogenicity in mice, and can induce an organism to generate high-titer antibody response biased to Th1 and high-level cellular immune response. Animal model experiments show that the vaccine composition can induce high-titer neutralizing antibodies and significantly reduce the viral load inside lung and turbinate tissues.

According to the invention, coronavirus spike protein RBD specific memory B cells are separated from PBMC of a rehabilitation person infected by a new coronavirus, amplification is carried out to obtain antibody light and heavy chain variable region sequences, a carrier is connected and introduced, recombinant expression is carried out to obtain a recombinant human monoclonal antibody, a monoclonal antibody which has high affinity with SARS-CoV-2 spike protein RBD, strong blocking force on the SARS-CoV-2 spike protein RBD and a host receptor ACEII and strong neutralizing activity on virus infected cells is selected from the monoclonal antibody, further screening is performed the ADE effect of the monoclonal antibody, and finally an anti-SARS-CoV-2S protein specific antibody MW07 which does not generate an ADE phenomenon is obtained.

The invention provides a novel coronavirus main protease inhibitor as well as a preparation method and application thereof. Specifically provided is a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or an isotope substitution form thereof. The compound can be used for effectively inhibiting the activity of SARS-CoV-2 Mpro, and can be used for preparing an SARS-CoV-2 Mpro inhibitor to block the replication and transcription of SARS-CoV-2 virus in the body of a patient. The compound disclosed by the invention has a very good application prospect in the preparation of an SARS-CoV-2 Mpro inhibitor, an SARS-CoV-2 resisting medicine and a medicine for preventing and / or treating novel coronavirus pneumonia.

The invention discloses a drug delivery system for external use containing the effective composition of bullatacin locality drug; the effective composition containing the bullatacin locality drug is dissolved in a mixed liquid of absolute alcohol and propylene glycol and fully stirred and mixed, and then prepared into the drug delivery system for external use; the drug delivery system comprises a patch, an aerosol or a film agent. Adoptions of the natural substance bullatacin extracted from cherimoya and an external using manner of the invention overcomes the shortcoming that the antitumor drugs and anti-AIDS drug have to be orally used or intravenously medicated, and the drug delivery system can ensure the drug to be absorbed through the skin, thus slowly releasing the drug and reducing the delivery dosage of the drug and the economic cost for the treatment.

The invention discloses a porcine epidemic diarrhea virus vaccine strain and a preparation method thereof. The vaccine strain is obtained by continuously transmitting FJzz1 to 200 generations in Vero cells. Low-generation FJzz1-F20 and high-generation FJzz1-F200 strains are selected to perform pathogenicity evaluation on piglets, and the result shows that the clinical manifestation of the piglets in a high-generation FJzz1-F200 infection group is obviously lighter than that of the piglets in an FJzz1-F20 infection group, and the diseased pigs do not die. Compared with the FJzz1-F20 infection group, the excrement toxin expelling amount of the piglets in the FJzz1-F200 infection group and the viral load in intestinal tissues are remarkably reduced, and the intestinal tissues are not subjected to obvious histopathological changes. Meanwhile, detection finds that the FJzz1-F200 infection group can induce high-level I-type and III-type interferon generation in the intestinal tissues. The research result shows that the FJzz1-F200 is weak in pathogenicity and has the potential of serving as a PEDV candidate attenuated vaccine strain.

The embodiment of the invention provides application of a lung-ventilating and toxin-vanquishing prescription or an extract of the lung-ventilating and toxin-vanquishing prescription to preparation of a medicine for preventing and / or treating pneumonia caused by influenza A virus H1N1, wherein the lung-ventilating and toxin-vanquishing prescription comprises the following components in parts by weight: 5-7 parts of raw ephedra, 28-32 parts of gypsum, 28-32 parts of raw coix seeds, 13-17 parts of bitter apricot kernels, 8-12 parts of rhizoma atractylodis lanceae, 13-17 parts of pogostemon cablin, 10-14 parts of artemisia apiacea, 28-32 parts of dried rhizoma phragmitis, 13-17 parts of pummelo peel, 18-22 parts of polygonum cuspidatum, 28-32 parts of verbena, 13-17 parts of semen lepidii and 8-12 parts of raw liquorice. The lung-ventilating and toxin-vanquishing prescription and the extract thereof provided by the invention can reduce the virus load, reduce the expression of proinflammatory factors, promote the expression of anti-inflammatory factors and improve pulmonary symptoms, so that the lung-ventilating and toxin-vanquishing prescription and the extract thereof can be used for preventing and / or treating pneumonia caused by the influenza A virus H1N1.

The invention relates to applications of a beta-glucan extract product in the immunological enhancement of poultry animals, and specifically provides a kit. The kit includes as follows: (1) an immune-enhancer used for enhancing the immunity of poultry animals and includes a beta-glucan extract product extracted from saccharomyces cerevisiae cell walls; and (2) a virus vaccine. Applications of thebeta-glucan extract product extracted from the saccharomyces cerevisiae cell walls in the preparation of the kit and immune-enhancer for enhancing the immunity of the poultry animals are also provided. Immunological enhancement can be performed on the poultry animals by using the beta-glucan extracted from the saccharomyces cerevisiae cell walls, so that lymphocyte proliferative response and T cell response of the poultry animals inoculated with the vaccine can be enhanced; viral load can be reduced; pathogenic rates or mortality can be lowered; antibodies can be generated in advance; antibodyproduction can be enhanced; and / or the diffusion of viruses can be restricted.

The invention discloses an anti-HPV infection medicine, which comprises the following raw material medicines in parts by weight: 10-20 parts of radix sophorae flavescentis, 10-20 parts of phellodendron amurense, 6-12 parts by weight of cortex dictamn, 4-8 parts by weight of safflower; 2-4 parts by weight of fructus cnidii; 3-5 parts by weight of Radix Astragali; 2-4 parts by weight of aloe; and 0.5-3 parts by weight of bunge corydalis herb. The invention discloses the anti-HPV infection medicine, the clinical symptoms and signs of patients can be obviously improved; the virus load capacity ofa virus infected person is effectively reduced; the medicine for treating the heart disease is prepared from the following raw materials: radix sophorae flavescentis, phellodendron amurense, cortex dictamni, safflower, fructus cnidii, Radix Astragali, aloe, bunge corydalis herb, borneol, perilla stems, eupatorium, campsis grandiflora, ground beetle, cortex magnoliae officinalis, rhinacanthus nasutus and rhizoma alismatis. Through reasonable compatibility of all the raw materials, the special performance and effects of all the raw materials are fully exerted, meanwhile, the complementary effectof all the raw materials is considered, the medicine effects supplement each other, the condyloma acuminatum treatment effect is remarkable, and no toxic or side effect exists.

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

The invention provides a traditional Chinese medicine composition for treating influenza. The traditional Chinese medicine composition is prepared from the following medicinal components in parts by weight: 8-12 parts of radix puerariae, 1-5 parts of roasted herba ephedrae, 18-22 parts of gypsum, 3-7 parts of semen armeniacae amarae, 4-8 parts of radix bupleuri, 4-8 parts of notopterygium root, 4-8 parts of folium isatidis, 4-8 parts of medicated leaven and 1-5 parts of liquorice. The flu is exterior cold and interior heat syndrome. The traditional Chinese medicine composition is capable of alleviating drug properties, preventing excessive warm-dryness of ephedra and preventing cold-cold stomach injury of gypsum. The medicines are used for supplementing the deficiency of monarch and ministerial drugs, so that the effects of relieving exterior syndrome, dispelling cold and clearing internal heat are enhanced. According to the formula, all the medicines are combined to achieve the effects of relieving exterior syndrome, dispelling cold and clearing internal heat, so that evil is removed, exterior syndrome is eliminated, qi and blood are smooth, and the whole function is achieved. Generally, the prescription is rigorous, the compatibility is proper, and the traditional Chinese medicine is clinically effective.

The invention belongs to the technical field of biology, and particularly relates to a 3D protein mutated O-type foot-and-mouth disease recombinant virus strain as well as construction and application thereof. The 403th methionine of the O-type foot and mouth disease virus 3D protein is mutated into alanine, the recombinant virus strain rFMDV-M403A with the mutated O-type foot and mouth disease virus 3D protein is successfully constructed and saved by using a reverse genetic technology, and amino acid of the recombinant virus strain can be stably mutated in a passage process; the growth speed of the mutant strain is slower than that of a wild strain, and the virus titer is remarkably reduced; in an individual experiment, neonatal mouse infection shows that the mutant strain can improve the survival rate of neonatal mice, and the virus load and tissue lesion in the liver are remarkably reduced. The attenuated foot-and-mouth disease recombinant virus strain provided by the invention provides important significance for deep understanding of a foot-and-mouth disease virus pathogenic mechanism and a prevention and control strategy, and also provides an important theoretical basis for further development of a foot-and-mouth disease genetic engineering vaccine.

The invention discloses an application of a non-ester nucleoside analogue or a pharmaceutically acceptable salt thereof or a composition containing the non-ester nucleoside analogue in preparation of a medicine for treating wetland virus diseases, and particularly, the nucleoside analogue is preferably ribavirin and favipiravir, has an obvious inhibition effect on WELV (Wetland Virus Virus) and is dose-dependent; the method has an excellent application prospect in treatment of wetland virus diseases.

The invention discloses insect lysozyme capable of preventing and treating rice virus diseases and application of the insect lysozyme. According to the invention, three pieces of lysozyme (RdLYZI1, RdLYZC1 and RdLYZC2) with remarkable inhibitory activity on various rice viruses are innovatively excavated from the body of a natural transmission vector insect of the viruses, and the amino acid sequences of the lysozyme are shown as SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15. The invention further discloses a preparation method of the lysozyme. Experimental verification shows that the lysozyme RdLYZI1, the lysozyme RdLYZC1 and the lysozyme RdLYZC2 can effectively inhibit replication and accumulation of various rice viruses in plants and vector insects, have a remarkable prevention and treatment effect on related virus diseases and relieve plant growth obstacles caused by the viruses. The invention provides a novel biological prevention and control strategy which is environment-friendly and high in targeting property for green prevention and control of rice virus diseases, and has an important application prospect.

The invention relates to an application of genipin-1-beta-D gentiobioside in preparation of medicines, in particular to an application of genipin-1-beta-D gentiobioside in preparation of medicines for treating respiratory tract inflammatory injury caused by coronavirus, respiratory syncytial virus or mycoplasma pneumoniae infection. The genipin-1-beta-D gentiobioside has the characteristics that the viral load, lung index and lung tissue inflammatory cytokines in lung tissues infected by coronavirus, respiratory syncytial virus or mycoplasma pneumoniae are reduced, and the genipin-1-beta-D gentiobioside has an obvious protective effect on death caused by coronavirus infection.

The invention discloses an anti-AIDS virus bullatacin patch for external use, which comprises a backing layer, a drug reservoir and an anti-sticking layer; a cotton medicinal non-woven fabrics with good permeability is used as the backing layer, a polymeric gel (an acrylate pressure-sensitive gel) as an adhesive; the patch comprises the prepared liquid of bullatacin, and a silicone-oil anti-sticking polyester film is functioned as an anti-sticking layer. The patch for external use has the advantages that not only the disadvantage of serious harmful and side effects of the existing oral or intravenous antitumor drug are solved, but also the disadvantage of heavy skin irritation and a certain extend of toxicity of traditional patches for external use are overcome, and the economic cost is reduced.

The invention discloses a micropeptide coded by long-chain non-coding RNA (Ribonucleic Acid) GAS5 and application thereof, the micropeptide is a micropeptide which is coded by long-chain non-coding RNA GAS5 and contains 50 amino acids, and the micropeptide is named as GAS5-P50. According to the scheme, a hemagglutination test and a plaque test detect that compared with a control group, the overexpressed micropeptide GAS5-P50 can obviously increase the HA titer and the virus load of the influenza virus, and the HA titer and the virus load of the influenza virus are obviously reduced by knocking down the expression of the GAS5-P50. The invention finds that the micropeptide GAS5-P50 coded by the long-chain non-coding RNA plays a role in promoting virus replication in the influenza virus infection process, molecules of the targeted micropeptide GAS5-P50 can be developed to serve as anti-influenza virus drugs, and a new choice is provided for prevention and treatment of influenza viruses.

The present invention provides a new vector for gene therapy said vector being therapeutically very efficient, viral particles comprising said vector, compositions comprising said viral particle, uses thereof, methods for the preparation of the vector), and therapies using said vector.

The invention belongs to the technical field of medicines, and discloses application of a compound in preparation of an antiviral drug. The compound N-[(2-methoxyphenyl) methyl]-2-[4-(4-methoxyphenyl)-2-oxybenzopyran-7-yl] oxyacetamide has a new application in medicine, and the application refers to a new application in virus resistance, especially in the aspect of pneumonia caused by coronavirus. The invention proves that the compound has the effects of remarkably inhibiting the lung index and reducing the lung virus load, and the effect of the compound is superior to that of a positive drug chloroquine phosphate and Lanhuaqing pestilence. The action mechanism of the compound for resisting viral pneumonia is related to the aspects of regulating expression of inflammatory factors, regulating differentiation of immune cells, inhibiting generation of free radicals and the like. The N-[(2-methoxyphenyl) methyl]-2-[4-(4-methoxyphenyl)-2-oxybenzopyran-7-yl] oxyacetamide can be used as a safe and effective novel clinical candidate drug for resisting viruses.

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

The invention discloses a drug delivery system for external use containing the effective composition of bullatacin locality drug; the effective composition containing the bullatacin locality drug is dissolved in a mixed liquid of absolute alcohol and propylene glycol and fully stirred and mixed, and then prepared into the drug delivery system for external use; the drug delivery system comprises apatch, an aerosol or a film agent. Adoptions of the natural substance bullatacin extracted from cherimoya and an external using manner of the invention overcomes the shortcoming that the antitumor drugs and anti-AIDS drug have to be orally used or intravenously medicated, and the drug delivery system can ensure the drug to be absorbed through the skin, thus slowly releasing the drug and reducing the delivery dosage of the drug and the economic cost for the treatment.

The present invention provides a compound of general formula I: and pharmaceutically acceptable salts and esters thereof. The provided compounds, compositions and methods are useful in the treatment of viral infections, particularly hepatitis C infections.

The invention discloses a medicine for preventing and treating infectious bronchitis in chickens and a preparation method thereof, and belongs to the field of medical technology. The raw materials for preparing the medicine include, by weight: 6-35 parts of ephedra, 10-30 parts of platycodon, 15-40 parts of phragmites, 5-30 parts of bitter almonds, 6-60 parts of licorice, 12-25 parts of plantain, 5-30 parts of fructus aurantii, 75-200 parts of gypsum, 1-18 parts of stemonae and 2-30 parts of mint. The preparation method includes the steps of crushing medicinal materials, enzymatic extraction, decoction, filtration, concentration and fine filtration. The experimental results show that the medicine of the present invention has a significant therapeutic effect, can effectively improve the cure rate of sick chickens, reduce the viral load in the body, and significantly improve the egg production and egg quality of sick laying hens. The composition also shows good safety and no obvious adverse reactions. Therefore, the present invention provides a new option for the prevention and treatment of infectious bronchitis in chickens, and has important application value.

The invention belongs to the technical field of biological medicine, and particularly relates to application of circular RNA as a marker in detection of hand-foot-and-mouth disease complicated nerve injury. According to the invention, the application of the hsacirc0069335 as the marker in predicting the hand-foot-and-mouth disease complicated nerve injury is found for the first time. In an external verification queue, a serum sample of a patient with a nerve injury symptom does not contain the marker, and the area under an ROC curve of the marker is 1, so that the marker can be used as the marker of the hand-foot-and-mouth disease complicated with the nerve injury and has excellent specificity and sensitivity. Furthermore, it is found that EV71 infection inhibits growth of Schwann cells and damage of myelin sheath formation, resulting in significant injury of a nervous system, and the EV71 infection is related to hsacirc0069335 / miR-29b-3p / PMP22 pathway. The discovery may provide a key molecular target for early warning and treatment of the severe hand-foot-and-mouth disease, so that the development progress of treatment drugs is accelerated.

The invention relates to a plant composition for the treatment or prevention of viral blood-borne diseases such as the diseases caused by the human immunodeficiency virus (HIV) or hepatitis C. According to the invention, the composition mainly includes flower of sulphur, a plant which contains catechins and a tannin agent, as well as a pharmaceutically acceptable medium. The invention also relates to the method for manufacturing said composition. The invention can be used in the field of treating or preventing viral blood-borne diseases such as the diseases caused by the human immunodeficiency virus (HIV) or hepatitis C.

The invention belongs to the field of medicine application and in particular relates to application of an AMPK (Adenosine 5'-monophosphate-activated protein kinase) agonist A769662 in preparing a medicine for treating porcine reproductive and respiratory syndromes. The invention finds that the AMPK agonist A769662 is capable of effectively inhibiting duplication of viruses of the porcine reproductive and respiratory syndromes, capable of remarkably alleviating clinical symptoms, reducing morbidity and mortality and reducing viral loads of pig tissue, and makes a basis for later research and development of medicines for treating the porcine reproductive and respiratory syndromes.

The invention belongs to the technical field of medicines and particularly relates to an artemisia-honeysuckle-flower-fructus gardeniae enema and a preparation method and application thereof. The enema is prepared from the following medicinal raw materials in parts by weight: 3-15 parts of honeysuckle flowers, 6-25 parts of artemisia apiacea and 1-2.99 parts of fructus gardeniae. The enema has theeffect of resisting CV-A6 and can be used for treating hand-foot-and-mouth diseases caused by CV-A6 infection.

The application belongs to the field of biology and particularly relates to a VP3 protein mutant recombinant Seneca virus strain and construction and application thereof. It is found for the first time that the lysine at the 82nd position of the VP3 protein of the Seneca virus is a key amino acid for regulating translation arrest, and after the site is mutated to alanine, the translation inhibition function of the VP3 protein is significantly weakened; further, through a molecular cloning technique, an infectious clone of the VP3 protein at the 82nd site is successfully constructed, and a corresponding recombinant virus strain rSVA VP3-K82A is rescued; compared with the wild type SVA, the virus proliferation ability of the recombinant virus strain is decreased, the virus titer is reduced, the immune escape ability is reduced, and the influence on the translation function of the host is weakened; not only does it provide a key tool for in-depth analysis of the functional mechanism of the VP3 protein in the virus replication cycle and immune escape, but also serves as a candidate strain of attenuated live vaccine, and provides a new idea for the development of Seneca virus prevention and control strategies.